Generex Clarifies Previous Announcement of Breast Cancer Study Interim Results

• Press Release
• Source: Generex Biotechnology Corp.
• On 9:15 am EST, Tuesday December 15, 2009

WORCESTER, Mass., Dec. 15, 2009 (GLOBE NEWSWIRE) -- On December 14, 2009, Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com) issued a press release announcing the presentation of interim results from a Phase II efficacy study of a novel immunotherapeutic vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), at the 32nd Annual San Antonio Breast Cancer Symposium (www.sabcs.org).

Related Quotes

SymbolPriceChange GNBT

0.64	0.00

that press release stated that "only half the number of patients in the treatment arm of the study relapsed compared to those not receiving the vaccine," and that "the results presented at the conference were those observed in patients 13.5 months after treatment." Those statements were incorrect. In fact, as COL George Peoples, MD reported to the symposium, at a median follow-up of 13 months, there were NO relapses in patients receiving the AE37 immunotherapeutic vaccine for breast cancer (0 of 49 patients) while relapses were observed in the control group (5 of 71 patients).

The ultimate goal of the study is to demonstrate that, after a follow-up period of 24 months, the relapse rate in the AE37 group of the study is less than half the relapse rate in the control group. The interim results of this study reported by COL Peoples clearly show that the study is on track to achieve that positive endpoint.